Tiziana Life Sciences is trading at $1.00 (+5.94%) following a disclosed insider purchase by Chairman Gabriele Cerrone.
- Cerrone acquired 42,357 additional shares at $0.99 per share, bringing his total ownership to 34.93% of the company.
- The insider buying serves as a notable stock-specific catalyst, as the move comes despite broader market pressure on the Nasdaq Composite and a risk-off environment for biotech stocks.